unknown
Stage
1
Investors
About
IGYXOS develops monoclonal antibody therapeutics aimed at improving infertility treatment by enhancing the activity of Follicle Stimulating Hormone (FSH) to improve reproductive health outcomes for men and women.
Explore IGYXOS's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.